The historical rank and industry rank for Petros Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
PTPI'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.14 Med: 0.37 Max: 0.67
Current: 0.35
During the past 5 years, the highest Equity to Asset Ratio of Petros Pharmaceuticals was 0.67. The lowest was 0.14. And the median was 0.37.
PTPI's Equity-to-Asset is ranked worse than 76.24% of 1086
companies
in the Drug Manufacturers industry
Industry Median: 0.58
vs PTPI: 0.35
Petros Pharmaceuticals Equity-to-Asset Historical Data
The historical data trend for Petros Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Petros Pharmaceuticals's Equity-to-Asset
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Petros Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Petros Pharmaceuticals Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Petros Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PTPI has been successfully added to your 